Cryolife (NYSE:CRY) Given a $35.00 Price Target by Canaccord Genuity Analysts

Canaccord Genuity set a $35.00 target price on Cryolife (NYSE:CRY) in a research note published on Wednesday morning, TipRanks reports. The firm currently has a buy rating on the medical equipment provider’s stock.

Other equities research analysts have also recently issued reports about the company. ValuEngine cut Cryolife from a strong-buy rating to a buy rating in a report on Wednesday, May 15th. TheStreet cut Cryolife from a b- rating to a c+ rating in a report on Wednesday, May 22nd. Zacks Investment Research raised Cryolife from a sell rating to a hold rating in a research report on Tuesday, April 23rd. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Cryolife in a research report on Sunday, May 12th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Cryolife has an average rating of Buy and an average price target of $31.91.

CRY stock traded down $0.71 during trading on Wednesday, hitting $28.31. 254,265 shares of the company traded hands, compared to its average volume of 136,304. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of 108.88 and a beta of 0.62. Cryolife has a 1 year low of $23.99 and a 1 year high of $36.05. The stock has a 50-day moving average of $29.97. The company has a debt-to-equity ratio of 0.86, a current ratio of 5.03 and a quick ratio of 3.69.

Cryolife (NYSE:CRY) last issued its earnings results on Tuesday, July 30th. The medical equipment provider reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.03. The company had revenue of $71.14 million during the quarter, compared to analysts’ expectations of $70.79 million. Cryolife had a return on equity of 3.85% and a net margin of 0.87%. Cryolife’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS. As a group, equities analysts predict that Cryolife will post 0.29 earnings per share for the current fiscal year.

In other news, VP Scott B. Capps sold 2,000 shares of the stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $28.55, for a total value of $57,100.00. Following the completion of the transaction, the vice president now owns 141,079 shares of the company’s stock, valued at approximately $4,027,805.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jean F. Holloway sold 8,654 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $32.00, for a total value of $276,928.00. Following the completion of the transaction, the vice president now directly owns 67,020 shares of the company’s stock, valued at approximately $2,144,640. The disclosure for this sale can be found here. Insiders have sold a total of 14,354 shares of company stock valued at $440,366 in the last ninety days. 4.40% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Advisors Asset Management Inc. raised its position in shares of Cryolife by 75.1% in the 1st quarter. Advisors Asset Management Inc. now owns 1,965 shares of the medical equipment provider’s stock worth $57,000 after acquiring an additional 843 shares in the last quarter. Quantamental Technologies LLC bought a new position in shares of Cryolife in the 1st quarter worth approximately $75,000. BNP Paribas Arbitrage SA raised its position in shares of Cryolife by 1,945.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,404 shares of the medical equipment provider’s stock worth $216,000 after acquiring an additional 7,042 shares in the last quarter. Piedmont Investment Advisors Inc. raised its position in shares of Cryolife by 5.9% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 8,602 shares of the medical equipment provider’s stock worth $251,000 after acquiring an additional 481 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in shares of Cryolife in the 4th quarter worth approximately $278,000. 71.10% of the stock is owned by hedge funds and other institutional investors.

About Cryolife

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Featured Story: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.